参考文献/References:
[1] Zhou M,Wang H,Zeng X,et al.Mortality,morbidity,and risk factors in China and its provinces,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2019,394:1145-1158.
[2]Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71:209-249.
[3]Zhang ZM,Lai EC,Zhang C,et al.The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus[J].Int J Surg,2015,20:8-16.
[4]Llovet JM,Bustamante J,Castells A,et al.Natural history of untreated nonsurgical hepatocellular carcinoma:rationale for the design and evaluation of therapeutic trials:Natural history of untreated nonsurgical hepatocellular carcinoma:rationale for the design and evaluation of therapeutic trials[J].Hepatology,1999,29:62-67.
[5]Zheng K,Zhu X,Fu S,et al.Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis:a randomized trial[J].Radiology,2022,303:455-464.
[6]Hu J,Bao Q,Cao G,et al.Hepatic arterial infusion chemotherapy using oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis[J].Cardiovasc Intervent Radiol,2020,43:996-1005.
[7]He M,Li Q,Zou R,et al.Sorafenib plus hepatic arterial infusion of oxaliplatin,fluorouracil,and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion:a randomized clinical trial[J].JAMA Oncol,2019,5:953-960.
[8]Wang X,Hu J,Cao G,et al.Phase Ⅱ study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma[J].Radiology,2017,283:580-589.
[9]Chen LT,Martinelli E,Cheng AL,et al.Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma:a TOS-ESMO initiative endorsed by CSCO,ISMPO,JSMO,KSMO,MOS and SSO[J].Ann Oncol,2020,31:334-351.
[10]Li QJ,He MK,Chen HW,et al.Hepatic arterial infusion of oxaliplatin,fluorouracil,and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma:a randomized phase Ⅲ trial[J].J Clin Oncol,2022,40:150-160.
[11]Kudo M,Kawamura Y,Hasegawa K,et al.Management of hepatocellular carcinoma in Japan:JSH consensus statements and recommendations 2021 update[J].Liver Cancer,2021,10:181-223.
[12]Kudo M,Finn R,Qin S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J].Lancet,2018,391:1163-1173.
[13]Yang Y,Chen L,Gu J,et al.Recurrently deregulated lncRNAs in hepatocellular carcinoma[J].Nat Commun,2017,8:14421.
[14]Wang D,Zhu Y,Tang J,et al.Integrative molecular analysis of metastatic hepatocellular carcinoma[J].BMC Med Genomics,2019,12:164.
[15]Li Z,Zhao M,Qi X,et al.Mechanisms of portal vein tumour thrombus formation and development in patients with hepatocellular carcinoma[J].J Cell Mol Med,2023,27:2103-2111.
[16]Zhou XH,Li JR,Zheng TH,et al.Portal vein tumor thrombosis in hepatocellular carcinoma:molecular mechanism and therapy[J].Clin Exp Metastasis,2023,40:5-32.
[17]Wang W,Lin H,Zhou L,et al.MicroRNA-30a-3p inhibits tumor proliferation,invasiveness and metastasis and is downregulated in hepatocellular carcinoma[J].Eur J Surg Oncol,2014,40:1586-1594.
[18]Hernandez-Gea V,Toffanin S,Friedman SL,et al.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma[J].Gastroenterology,2013,144:512-527.
[19]Chen S,Dong Z,Yang P,et al.Hepatitis B virus X protein stimulates high mobility group box 1 secretion and enhances hepatocellular carcinoma metastasis[J].Cancer Lett,2017,394:22-32.
[20]王晓东,杨仁杰,邹英华,等.改良式经皮肝动脉化疗药盒植入技术中国专家共识(2022版)[J].介入放射学杂志,2022,31:633-641.
[21]Galle PR,Finn RS,Qin SK,et al.Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma(IMbrave150):an open-label,randomised,phase 3 trial[J].Lancet Oncol,2021,22:991-1001.
[22]Florea AM,Büsselberg D.Cisplatin as an anti-tumor drug:cellular mechanisms of activity,drug resistance and induced side effects[J].Cancers(Basel),2011,3:1351-1371.
[23]Kaibori M,Matsushima H,Ishizaki M,et al.The impact of Sorafenib in combination with intermittent hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with major vascular invasion[J].Cancer Invest,2022,40:81-89.
[24]Iwamoto H,Shimose SG,Shirono T,et al.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity[J].Clin Mol Hepatol,2023,29:593-604.
[25]Niizeki T,Sumie SJ,Torimura T,et al.Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy[J].J Gastroenterol,2012,47:686-695.
[26]Kudo M,Ueshima K,Yokosuka O,et al.Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma(SILIUS):a randomised,open label,phase 3 trial[J].Lancet Gastroenterol Hepatol,2018,3:424-432.
[27]Choi JH,Chung WJ,Bae SH,et al.Randomized,prospective,comparative study on the effects and safety of sorafenib vs.hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J].Cancer Chemother Pharmacol,2018,82:469-478.
[28]Tanaka T,Iwamoto H,Fujihara M,et al.Efficacy of a glass membrane emulsification device to form mixture of cisplatin powder with lipiodol on transarterial therapy for hepatocellular carcinoma[J].Cardiovasc Intervent Radiol,2021,44:766-773.
[29]Nagamatsu H,Sumie SJ,Niizeki T,et al.Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma:multicenter phase Ⅱ study[J].Cancer Chemother Pharmacol,2016,77:243-250.
[30]Iwamoto H,Niizeki T,Nagamatsu H,et al.The clinical impact of hepatic arterial infusion chemotherAPY new-FP for hepatocellular carcinoma with preserved liver function[J].Cancers(Basel),2022,14:4873.
[31]Lyu N,Wang X,Li JB,et al.Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma:a biomolecular exploratory,randomized,phase Ⅲ trial(FOHAIC-1)[J].J Clin Oncol,2022,40:468-480.
[32]Fu Y,Peng W,Zhang W,et al.Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis[J].J Gastroenterol,2023,58:413-424.
[33]Xu YJ,Lai ZC,He MK,et al.Toripalimab combined with hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma[J].Technol Cancer Res Treat,2021,20:15330338211063848.
[34]Liu BJ,Gao S,Zhu X,et al.Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma[J].Immunotherapy,2021,13:1395-1405.
[35]Cai M,Liang L,Zhang J,et al.Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis:a multicenter retrospective cohort study[J].Int J Surg,2024,Epub ahead of print.
[36]Lin Z,Chen D,Hu X,et al.Clinical efficacy of HAIC(FOLFOX)combined with lenvatinib plus PD-1 inhibitors vs.TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas[J].Am J Cancer Res,2023,13:5455-5465.
[37]Yuan Y,He W,Yang Z,et al.TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus:a propensity score matching study[J].Int J Surg,2023,109:1222-1230.
[38]Obi S,Yoshida H,Toune RS,et al.Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion[J].Cancer,2006,106:1990-1997.
[39]Assenat E,Pageaux GP,Thezenas S,et al.Sorafenib alone vs.sorafenib plus GEMOX as 1st-line treatment for advanced HCC:the phase Ⅱ randomised PRODIGE 10 trial[J].Br J Cancer,2019,120:896-902.
[40]Liu Y,Yue H,Xu S,et al.First-line gemcitabine and oxaliplatin(GEMOX)plus sorafenib,followed by sorafenib as maintenance therapy,for patients with advanced hepatocellular carcinoma:a preliminary study[J].Int J Clin Oncol,2015,20:952-959.
(收稿日期:2024-04-11)
(本文编辑:茹 实)
相似文献/References:
[1]郭丽萍,张晓玲,王莉娜.经导管肝动脉化疗栓塞联合高强度聚焦超声治疗原发性肝癌的护理[J].介入放射学杂志,2010,(04):328.
GUO Liping,ZHANG Xiaoling,WANG Lina.The nursing care for patients of hepatocellular carcinoma treated with transcatheter hepatic arterial chemoembolization and high intensive focus ultrasound[J].J Intervent Med,2010,(04):328.
[2]沈海洋,杨光,刘瑞宝,等.肝右叶前、后段原发性肝癌动脉化疗栓塞术后近期疗效比较[J].介入放射学杂志,2010,(05):382.
SHEN Haiyang,YANG Guang,LIU Ruibao,et al.Short－term effects of TACE for primary hepatocellular carcinoma of the right hepatic lobe：a comparison between the lesions in anterior segments and the lesions in posterior segments[J].J Intervent Med,2010,(04):382.
[3]池嘉昌,沈加林,许建荣,等.全肝CT灌注成像在原发性肝癌TACE术后局部病灶活性评估中的临床应用[J].介入放射学杂志,2010,(07):540.
CHI Jiachang,SHEN Jialin,XU Jianrong,et al.Clinical application of whole－liver perfusion－enhanced CT imaging in evaluating the activity of residual hepatocellular carcinoma after TACE[J].J Intervent Med,2010,(04):540.
[4]翁志成,杨维竹,江娜,等.CT引导下１２５I放射性粒子植入治疗肝癌门静脉癌栓的疗效评价[J].介入放射学杂志,2010,(07):535.
WENG Zhicheng,YANG Weizhu,JIANG Na,et al.Evaluation of CT－guided１２５I seed implantation combined with transcatheter arterial chemoem－bolization in treating portal vein tumor thrombus associated with hepatocellular carcinoma[J].J Intervent Med,2010,(04):535.
[5]王悍 王精兵 张贵祥 王麟川.肝细胞癌动脉化疗栓塞术后并发脑梗死一例[J].介入放射学杂志,2005,(04):442.
WANG Han WANG Jing-bing ZHANG Gui-xiang WANG Lin-chuan.Cerebral infarction aften transaterial shemoembolization for hepatocellular carcinoma a cage report[J].J Intervent Med,2005,(04):442.
[6]张绪敬,程佩芳,董光,等.原发性肝癌经导管化疗、栓塞前后血中凝血酶原变化的研究[J].介入放射学杂志,1992,(01):33.
[7].关于召开“全国肝癌介入治疗研讨会”的通知[J].介入放射学杂志,1995,(04):200.
[8]欧阳墉,马和平,张学军,等.肝细胞癌的鉴别诊断——附10例分析[J].介入放射学杂志,1996,(01):40.
[9]周斌,李征然,钱结胜,等.原发性肝癌肝移植后肿瘤复发的化疗栓塞治疗[J].介入放射学杂志,2009,(03):185.
ZHOU Bin,LI Zhengran,QIAN Jiesheng,et al.Chemoembolization for recurrent hepatocellular carcinoma after liver transplantation[J].J Intervent Med,2009,(04):185.
[10]黄渊全,贾中芝,冯耀良,等.CT灌注成像在肝癌TACE术后疗效评价中的应用价值[J].介入放射学杂志,2009,(06):437.
HUANG Yuan-quan,JIA Zhong-zhi,FENG Yao-liang,et al.Clinical application of CT perfusion imaging in estimating the efficacy of transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma[J].J Intervent Med,2009,(04):437.